Biotech Regeneron Pharmaceuticals is shaping up to have an eventful year. Regeneron (REGN) has already become a leading stock thanks to the successful launch of Eylea, its treatment for wet age-related macular degeneration, a type of vision loss. It touched a record high Monday. By August, the product is also expected to be approved for diabetic macular edema. Attention, however, is now shifting to the other drugs in the company’s pipeline. Wall
Regeneron Pharmaceuticals beat analysts’ Q4 estimates and guided this year’s drug sales in line with views Tuesday, and also said it’s building a new facility in low-tax Ireland. The stock popped to a new high, closing up 7.4% at 326.52. Regeneron’s (REGN) sales in the quarter totaled $610 million, up 47% from the year-earlier quarter and $29 million more than analysts’ consensus. Non-GAAP net income rose 52% to $2.24 a share. Analysts’ estimates
Regeneron Pharmaceuticals (REGN) beat analysts’ expectations with its Q4 report Tuesday, sending shares up 2.5% in early trading in the stock market today, though its guidance on main drug Eylea was merely in line with expectations. Sales in the quarter totaled $610 million, up 47% from the year-earlier quarter and $29 million more than analysts’ consensus. Non-GAAP net income rose 52% to $2.24 a share. Thomson Reuters’ estimates are not entirely